Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,921 | 4,372 | 6,257 | 8,500 | 429 |
| Receivables | N/A | 1,250 | N/A | N/A | N/A |
| TOTAL | $3,378 | $5,768 | $6,906 | $8,635 | $855 |
| Non-Current Assets | |||||
| PPE Net | 287 | 60 | 69 | 76 | 88 |
| Other Non-Current Assets | 48 | 48 | 48 | 47 | 47 |
| TOTAL | $334 | $108 | $117 | $123 | $135 |
| Total Assets | $3,712 | $5,876 | $7,023 | $8,758 | $990 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 867 | 874 | 930 | 930 | 936 |
| Accrued Expenses | 443 | 962 | 795 | 565 | 814 |
| TOTAL | $1,368 | $1,872 | $1,797 | $1,602 | $1,795 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 27 |
| Other Non-Current Liabilities | 1,578 | 1,339 | 1,102 | 946 | 2,090 |
| TOTAL | $1,729 | $1,415 | $1,139 | $994 | $2,172 |
| Total Liabilities | $3,096 | $3,288 | $2,936 | $2,595 | $3,967 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 310 | 286 | 279 | 265 | 265 |
| Common Shares | 9 | 9 | 8 | 8 | 3 |
| Retained earnings | -141,999 | -139,450 | -136,811 | -133,710 | -131,743 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $616 | $2,589 | $4,087 | $6,163 | $-2,977 |
| Total Liabilities And Equity | $3,712 | $5,876 | $7,023 | $8,758 | $990 |